Ongoing treatment(s)-Bone marrow transplant Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Bone marrow transplant Posts on Medivizor

Comparing the long-term outcomes of umbilical cord blood donor versus unrelated donor transplantation in patients with acute myeloid leukemia.

Comparing the long-term outcomes of umbilical cord blood donor versus unrelated donor transplantation in patients with acute myeloid leukemia.

Posted by on Aug 15, 2021 in Leukemia | 0 comments

In a nutshell This study compared the long-term outcomes of umbilical cord (UC) blood transplantation versus unrelated donor transplantation (UD) in patients with acute myeloid leukemia (AML). The data showed that long-term outcomes for patients in complete remission two years after transplantation was not impacted by donor...

Read More

Consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia

Consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia

Posted by on May 30, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if consolidation chemotherapy before reduced-intensity conditioning (RIC) allogeneic hemopoietic stem cell transplant (alloHSCT) improved outcomes for patients with acute myeloid leukemia (AML).  This study concluded that exposure to consolidation chemotherapy before RIC alloHSCT may help patients...

Read More

Allogenic versus autologous hematopoietic stem cell transplant for patients with acute promyelocytic leukemia

Allogenic versus autologous hematopoietic stem cell transplant for patients with acute promyelocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) for patients with acute promyelocytic leukemia (APL) in second complete remission (CR2).  This study concluded that autoHSCT resulted in better outcomes for these patients.   Some background...

Read More

Can lenalidomide maintenance improve survival after autologous hematopoietic stem-cell transplantation in patients with mantle cell lymphoma?

Can lenalidomide maintenance improve survival after autologous hematopoietic stem-cell transplantation in patients with mantle cell lymphoma?

Posted by on Feb 6, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether lenalidomide maintenance therapy after intensive chemoimmunotherapy and first-line autologous hematopoietic stem-cell transplantation (AHSCT) improved the outcomes of patients with mantle cell lymphoma (MCL). The data showed that lenalidomide maintenance after AHSCT improved the survival without...

Read More

Recombinant human granulocyte colony-stimulating factor and decitabine treatment delay relapse after transplant for patients with acute myeloid leukemia

Recombinant human granulocyte colony-stimulating factor and decitabine treatment delay relapse after transplant for patients with acute myeloid leukemia

Posted by on Dec 12, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if the combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF; Filgrastim) and decitabine (Dacogen) would be effective in preventing relapse after transplant for patients with high-risk (HR) acute myeloid leukemia (AML).   This study...

Read More

Evaluating sorafenib maintenance therapy in patients with acute myeloid leukemia with FLT3-ITD mutation undergoing allogeneic HSCT

Evaluating sorafenib maintenance therapy in patients with acute myeloid leukemia with FLT3-ITD mutation undergoing allogeneic HSCT

Posted by on Sep 25, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated outcomes of sorafenib (Nexavar) maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutation (abnormal gene). The authors found that this therapy was effective and tolerable after aHSCT in such patients. Some...

Read More

Does donor type impact on outcomes of stem cell transplant for very high-risk acute lymphoblastic leukemia pediatric patients?

Does donor type impact on outcomes of stem cell transplant for very high-risk acute lymphoblastic leukemia pediatric patients?

Posted by on Aug 23, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if donor type impacts on the overall outcomes of allogeneic stem cell transplant for children with very high-risk acute lymphoblastic leukemia.   This study concluded that donor type does impact on these patients and that worse outcomes are seen with mismatched donors.   Some...

Read More

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Posted by on Aug 16, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the role of antithymocyte globulin in preventing graft-versus-host disease after matched sibling donor transplantation.  This study concluded that this treatment can reduce the occurrence of graft-versus-host-disease in these patients.   Some background One...

Read More

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Evaluating antithymocyte globulin in preventing graft-versus-host-disease after matched sibling donor transplantation

Posted by on Aug 16, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the role of antithymocyte globulin in preventing graft-versus-host disease after matched sibling donor transplantation. This study concluded that this treatment can reduce the occurrence of graft-versus-host-disease in these patients.   Some background One treatment option for patients with blood...

Read More

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....

Read More

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Posted by on Jun 21, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan). This study concluded that cryopreservation (CP) does not affect the outcomes of HSCT in these patients....

Read More

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Higher or lower radiotherapy dose for patients with non-Hodgkin lymphoma undergoing stem cell transplantation?

Posted by on May 26, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined how effective and safe a higher radiotherapy dose was for patients with non-Hodgkin lymphoma (NHL) undergoing stem cell transplantation (SCT). The authors found that patients who received a lower radiotherapy dose survived longer and had fewer side effects than the higher dose. Some background NHL is a cancer of...

Read More